Evoke Pharma (EVOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 10,249 | 5,181 | 2,509 | 1,618 | 23 |
| Cost of Goods | 357 | 202 | 370 | 328 | 87 |
| Gross Profit | 9,893 | 4,979 | 2,138 | 1,290 | -64 |
| Operating Expenses | 15,454 | 12,612 | 10,295 | 9,770 | 13,070 |
| Operating Income | -5,204 | -7,431 | -7,786 | -8,152 | -13,047 |
| Interest Expense | 501 | 500 | 500 | 500 | 113 |
| Other Income | 353 | 139 | 62 | 114 | 6 |
| Pre-tax Income | -5,352 | -7,792 | -8,224 | -8,538 | -13,155 |
| Net Income Continuous | -5,352 | -7,792 | -8,224 | -8,538 | -13,155 |
| Net Income | $-5,352 | $-7,792 | $-8,224 | $-8,538 | $-13,155 |
| EPS Basic Total Ops | -2.81 | -27.97 | -31.45 | -38.18 | -74.94 |
| EPS Basic Continuous Ops | -2.81 | -27.93 | -31.40 | -38.22 | -74.37 |
| EPS Diluted Total Ops | -2.81 | -27.97 | -31.45 | -38.18 | -74.94 |
| EPS Diluted Continuous Ops | -2.81 | -27.93 | -31.40 | -38.22 | -74.37 |
| EPS Diluted Before Non-Recurring Items | -2.81 | -27.97 | -31.45 | -38.91 | -74.94 |
| EBITDA(a) | $-5,204 | $-7,431 | $-7,786 | $-8,152 | $-13,047 |